Sheppard, Michael <br/><br/>
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.  [electronic resource] 

 -  Pituitary  Jun 2015 
 - 385-94 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7403 
<br/><br/><label>Standard No.: </label>10.1007/s11102-014-0585-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acromegaly--blood<br/>Adenoma--blood<br/>Adult<br/>Aged<br/>Biomarkers, Tumor--blood<br/>Blood Glucose--drug effects<br/>Brazil<br/>Double-Blind Method<br/>Europe<br/>Female<br/>Growth Hormone-Secreting Pituitary Adenoma--blood<br/>Human Growth Hormone--blood<br/>Humans<br/>Hyperglycemia--blood<br/>Insulin-Like Growth Factor I--metabolism<br/>Male<br/>Middle Aged<br/>North America<br/>Remission Induction<br/>Somatostatin--adverse effects<br/>Time Factors<br/>Treatment Outcome<br/>Young Adult